Neuren Pharmaceuticals stock
Price history
+13.41% over the period1 year: from $18.49 (November 20, 2025) to $20.97 (November 20, 2026), +13.41%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $20.97 |
| October 30, 2026 | $20.36 |
| September 30, 2026 | $20.35 |
| August 31, 2026 | $19.74 |
| July 31, 2026 | $18.00 |
| June 30, 2026 | $17.75 |
| May 29, 2026 | $14.54 |
| April 30, 2026 | $12.46 |
| March 31, 2026 | $11.81 |
| February 27, 2026 | $13.05 |
| January 30, 2026 | $16.69 |
| December 31, 2025 | $18.61 |
| November 28, 2025 | $19.64 |
| November 20, 2025 | $18.49 |
At a glance
The company
Biopharmaceutical company developing drugs for neurological disorders including Rett syndrome, Fragile X syndrome and other rare genetic conditions
Latest results
Quarter to June 30, 2026 · EPS $0.04 (estimate $32.00)
Next event
TickerLandia's take on Neuren Pharmaceuticals
- Pricier than usual relative to earnings: P/E on the latest fiscal year 90 vs a median of 45 over its last 5 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 144 vs 68 (+111%) in a group of 6.
- Strong point: Market momentum (75/100 in its group). Weak point: Profitability (43/100).
- “Beat the market” (Australia): No. 2 of 195.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−14.58% from the 52-week high
Analysts · 6 analysts
Average target$27.03+28.91% vs. price
Buy 6 · Hold 0 · Sell 0 · Strong buy
TickerLandia Fingerprint: Neuren Pharmaceuticals
Compared with similar companies: very high price.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricevery high84
How much it costs relative to what it produces.
Metric Value Position in group Price/sales 39.4 85 Forward P/E 36.1 74 Price/book 8.21 70 P/E (trailing 12 months) 144.0 94 EV/EBITDA 180.3 96 Profitabilityaverage43
How much it earns on revenue and capital.
Metric Value Position in group ROE 6.2% 35 Net margin 29.1% 78 ROA 2.6% 39 Gross margin 29.6% 11 Operating margin 19.9% 53 Earnings stabilityaverage47
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 142.3% 32 Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 62 Growthaverage49
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +17.30% 44 Earnings growth (year over year) −67.30% 28 Average revenue growth (3 years) +61.26% 76 Dividendhigh62
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 1 year 30 Payout ratio 100.0% 92 Dividend yield 1.4% 64 Market momentumstrong75
How the stock has moved compared with the market.
Metric Value Position in group Distance from 200-day average +26.69% 97 Relative strength (3 months) −4.20% 38 Relative strength (6 months) +66.95% 99 1-year return +13.41% 64 Riskhigh74
How much the price swings.
Metric Value Position in group Beta (1 year) 1.83 89 Volatility (60 days) 46.3% 67 Maximum drawdown (12 months) 44.9% 67
1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Neuren Pharmaceuticals is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Neuren Pharmaceuticals's P/E today is 90.1, above the median of its last 5 fiscal years (45.2; between 11.5 and 91.4 from 2017 to 2025). Neuren Pharmaceuticals's P/E (trailing 12 months): 144.0, +111% against the median of a group of 6 similar companies (68.2).
Compared with 6 similar companies
| Metric | Neuren Pharmaceuticals | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 144.0 | High | |
| Forward P/E | 36.1 | Middle | |
| Operating margin | 19.9% | Middle | |
| ROE | 6.2% | Middle | |
| Price/book | 8.21 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Neuren Pharmaceuticals. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$33.16M
Latest quarter · Q2 2026
Net income
$4.85M
Latest quarter · Q2 2026
Quarterly net margin
14.6%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $2.74B
- P/E
- 144.0
- EPS
- $0.15
- Volume
- 37.24K
- Daily trading
- €6.45M
- Dividend yield
- 0.72%
- Last ex-dividend on September 15, 2026
How Neuren Pharmaceuticals is changing
All resultsRevenue grew 146.0% a year on average over the last 5 years
Operating margin rose from −4.7% to 34.1%
Profits turn into cash: free cash flow equal to 91% of net income
Returns
Neuren Pharmaceuticals returns with dividends
$1,000 invested in Neuren Pharmaceuticals 5 years ago, on November 22, 2021, would be worth $11,397 today: +1,039.67% in total, +62.79% per year. This is the price return only: dividends are excluded.
| Period | Neuren Pharmaceuticals | S&P/ASX 200 | $1,000 becomes |
|---|---|---|---|
| 1 month | +6.88% | −2.54% | $1,069 |
| 6 months | +68.84% | +1.13% | $1,688 |
| Year to date | +12.68% | −1.40% | $1,127 |
| 1 year | +14.23% | +0.47% | $1,142 |
| 3 years | +42.07% | +21.74% | $1,421 |
| 5 years | +1,039.67% | +16.86% | $11,397 |
| 10 years | +1,488.64% | +60.57% | $15,886 |
Over the last 6 months it has done better than 95% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P/ASX 200: price only. Calculate your investment
The chart in detail
Neuren Pharmaceuticals: technical analysis
Neuren Pharmaceuticals is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 16.5% below its all-time closing high ($25.11, December 28, 2023).
- Trend
- Upward
- RSI (14 sessions)
- 45
- Between 30 and 70
- vs 200-session average
- +26.69%
Support and resistance
Price areas where Neuren Pharmaceuticals has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$21.07+0.46%3 touches, last on September 17, 2026
- Last price$20.97
- Support$20.22−3.60%2 touches, last on December 23, 2025
- Support$19.46−7.18%3 touches, last on September 29, 2026
- Support$18.59−11.34%5 touches, last on October 27, 2026
Volatility and risk
Over the last year it has moved more than the S&P/ASX 200.
- Beta (1 year) vs S&P/ASX 200
- 1.83
- Volatility (60 sessions, annualised)
- 46.3%
- Largest fall in the last year
- −44.89%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Neuren Pharmaceuticals: seasonality
Average monthly price change over 22 years
Over the last 22 years, the strongest month for Neuren Pharmaceuticals has been April: +34.24% on average, positive in 11 years out of 22. The weakest has been February: −6.20% on average, positive in 6 years out of 21. November, the current month, has been positive in 13 years out of 21 (+7.27% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.31% | −2.64% | 7 of 21 |
| February | −6.20% | −5.88% | 6 of 21 |
| March | −4.82% | −6.14% | 7 of 22 |
| April | +34.24% | +0.31% | 11 of 22 |
| May | +2.66% | 0.00% | 10 of 22 |
| June | −2.63% | −4.19% | 8 of 22 |
| July | +10.29% | +5.46% | 15 of 22 |
| August | −3.98% | −2.34% | 8 of 22 |
| September | +1.32% | −3.17% | 10 of 22 |
| October | +10.94% | +5.72% | 14 of 22 |
| November | +7.27% | +9.14% | 13 of 21 |
| December | +3.52% | −0.63% | 10 of 21 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Neuren Pharmaceuticals and its competitors
With eight employees and revenue of AUD 64.6 million in the fiscal year ended December 2025, Neuren Pharmaceuticals develops drugs for neurological disorders. It develops and commercializes DAYBUE (trofinetide) for Rett syndrome in adults and in patients aged 2 years and older, and runs a Phase 2 trial for Fragile X syndrome. Its NNZ-2591 compound has completed Phase 2 testing for Phelan-McDermid syndrome, is in Phase 2 for Angelman and Pitt Hopkins syndromes, and is in preclinical stage for Prader-Willi syndrome, hypoxic ischemic encephalopathy and SYNGAP1.
- Headquarters
- Hawthorn East, Australia
- Employees
- 8
- Founded
- 2001
- Chief executive
- Jonathan Pilcher
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Neuren PharmaceuticalsNEU | $1.83B | 19.9% | 144.0 | +68.84% |
| MesoblastMSB | $1.48B | -42.6% | — | −14.82% |
| InSilico Medicine Cayman TopCo3696 | $2.59B | -6.9% | — | −36.46% |
| Telix PharmaceuticalsTLX | $2.92B | 6.2% | 92.3 | −7.71% |
| Metis TechBio7666 | $1.11B | -131.2% | — | −63.08% |
| 3SBio1530 | $4.56B | 60.3% | 3.90 | −34.08% |
Same industry or related industries, similar size. Compare Neuren Pharmaceuticals with its competitors · Full profile
More on Neuren Pharmaceuticals
- Neuren Pharmaceuticals revenue and financials
- Neuren Pharmaceuticals dividend and valuation
- Neuren Pharmaceuticals stock return
- Neuren Pharmaceuticals employees, headquarters and business
